基于网络药理学探讨白芍治疗非酒精性脂肪性肝病的作用机制

Exploration of the Mechanism of Paeoniae in the Treatment of Non-alcoholic Fatty Liver Disease Based on Network Pharmacology

目的本研究运用网络药理学的研究方法探索白芍治疗非酒精性脂肪性肝病的作用机制。方法通过TCMSP、Swiss Target Prediction数据库筛选出白芍的有效成分及主要成分靶点;运用Genecards数据库查找疾病靶点基因;通过Venny2.1在线作图工作平台获取白芍成分靶点与疾病靶点的交集图,通过Cytoscape3.7.2软件构建白芍-活性成分-靶点网络;并通过String数据库构建PPI蛋白网络、DAVID数据库进行基因GO分析和KEGG通路分析。结果通过筛选共获得白芍有效成分13个,药物靶点基因264个,疾病靶点基因有950个,共取得交集靶点基因83个。基因GO分析得出白芍主要参与RNA聚合酶II启动子转录的正向调节、细胞凋亡过程的负调节、蛋白质结合等多种生物过程。KEGG通路分析得出癌症的途径、HIF-1信号通路、MAPK信号通路、PI3K-Akt信号通路、脂质和动脉粥样硬化等20条与之密切的相关通路。结论白芍通过多靶点、多途径发挥其治疗非酒精性脂肪性肝病的作用。

Objective:To explore the mechanism of Paeoniae in the treatment of non-alcoholic fatty liver disease by using the method of network pharmacology.Methods:The effective components and main component targets of Paeoniae were screened by TCMSP and Swiss Target Prediction database.The target gene of the disease was found by using Genecards database,and the intersection map of Paeoniae component target and disease target was obtained by Venny2.1 online mapping platform.And then a network of Paeoniae-active-component-target was constructed by Cytoscape3.7.2 software and PPI protein network and DAVID database were constructed by String database to make gene GO analysis and KEGG pathway analysis.Results:A total of 13 effective components,264 drug target genes,950 disease target genes and 83 intersection target genes were obtained through screening.The gene GO analysis showed that Paeoniae was mainly involved in the positive regulation of RNA polymerase II promoter transcription,the negative regulation of apoptosis,protein binding and other biological processes.The KEGG pathway analysis showed 20 closely related pathways,including cancer pathway,HIF-1 signaling pathway,MAPK signaling pathway,PI3K-Akt signaling pathway,lipid and atherosclerosis.Conclusion:Paeoniae exerts its role in the treatment of non-alcoholic fatty liver disease through multi-target and multi-pathway.